Goldman Sachs Launches China AI Healthcare Index: 8 Companies on the List with Top Gainer Up 69% in a Month

 

In the US stock market, AI medical concept stocks have been on a steady rise, and this trend has recently extended to the Hong Kong stock market. Goldman Sachs has introduced the China AI Healthcare Index, highlighting some of the most promising players in the sector.

 

The index includes several Hong Kong-listed companies, with standout performers like MedLive (02192.HK) and XtalPi (02228.HK), whose shares have surged by over 69% and 60%, respectively, since February. Other notable names include Alibaba Health (00241.HK), JD Health (06618.HK), Ping An Health (01833.HK), Yidu Tech (02158.HK), MedBot (02252.HK), and Gushengtang (02273.HK), all of which have seen significant gains recently.

 

 

 

A leader in AI-driven drug discovery, XtalPi combines quantum physics and robotics to accelerate the development of new drugs. Its innovative business model integrates AI with automated chemical synthesis, potentially revolutionizing drug development and market delivery.

 

Leveraging its parent company's AI capabilities, Alibaba Health enhances its e-commerce platform and improves patient care through AI-powered diagnostic tools and personalized medicine recommendations.

 

JD Health focuses on AI-driven health management, offering personalized medication guidance and health risk assessments. Its collaboration with DeepSeek for an AI health assistant aims to streamline chronic disease management and post-operative care.

 

Known for its 24/7 AI-powered family doctor service, Ping An Health integrates DeepSeek's AI to enhance diagnostic accuracy and patient management, potentially making healthcare more accessible and efficient.

 

Yidu Tech's integration of DeepSeek into its "AI medical brain" YiduCore marks a significant advancement. The company processes billions of medical records, and this move could further improve its ability to provide precise disease insights and enhance healthcare efficiency.

 

MedBot specializes in developing surgical instruments, focusing on the design, R&D, and commercialization of innovative surgical robots. Key products include the TUMY endoscopic surgical robot, Dragonfly Eye 3D laparoscope, and Honghu orthopedic surgical robot, used in minimally invasive surgeries. Additionally, MedBot offers training services for its surgical robots.

 

A leading chain in Traditional Chinese Medicine (TCM) services, Gushengtang has partnered with DeepSeek to advance intelligent diagnosis, personalized care, and efficient management in "TCM + AI," marking a significant milestone in the industry's development.

 

MedLive operates an online physician platform with core business areas including precision marketing and enterprise solutions. Its independently developed medical vertical field model, registered with the National Internet Information Office, highlights its technical expertise. Partnering with Azure OpenAI, MedLive has integrated ChatGPT via Azure, enhancing its digital intelligence capabilities, particularly in improving content production efficiency and enabling smarter user interactions.

 

 

The AI healthcare sector is poised for explosive growth. According to Guosen Securities, the global market for AI solutions in healthcare is expected to grow from $13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5%. This growth is driven by the increasing adoption of AI in drug discovery, diagnostics, and personalized medicine.

 

Sinolink also highlights that AI-related healthcare stocks are gaining traction, with "AI + healthcare" and innovative drug development being the key investment themes for 2025. The sector is expected to see a strong recovery post-Q1 2025, driven by both innovation and a rebound in earnings.

 

 

The launch of the China AI Healthcare Index by Goldman Sachs underscores that AI in healthcare is no longer a futuristic concept—it's here, and it's growing rapidly. Companies like XtalPi and YiduTech are at the forefront of this revolution, and their integration of advanced AI technologies could significantly reduce costs and improve healthcare outcomes.

 

However, while the potential is enormous, investors should remain cautious. The sector is still in its early stages, and regulatory challenges, data privacy concerns, and the high cost of AI implementation could pose risks. That said, for those willing to take on some risk, the AI healthcare space offers a compelling growth story. #china #hkex